… ER)–positive, HER2-negative advanced breast cancer who progressed after endocrine therapy … between fulvestrant (Faslodex) or exemestane (Aromasin), was also given at the … patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, …

… hormone receptor-positive (HR+) breast cancer,” said Jennifer Schneiders, … the landmark Tamoxifen and Exemestane Trial (TEXT) … + breast cancer.2* About the Breast Cancer Index Test The Breast Cancer Index … approvals. For the Breast Cancer Index Intended Use …

… (ER)–positive, HER2-negative advanced breast cancer across clinically and genomically defined … (ET) with fulvestrant (Faslodex) or exemestane. “The combination arm was added … without abemaciclib (abeam) in advanced breast cancer (ABC): a subgroup analysis in …

… expression profiles, breast cancers are classified into … breast cancer (TNBC).4 ER positive breast cancer represents approximately 70% of all breast cancer … tamoxifen or exemestane offers greater … of prescriptions for breast cancer patients. The prescription …

… - breast cancer @ Metastatic HR+/HER2- Breast Cancer Treatment  Metastatic HR+/HER2- Breast Cancer Emerging … breast cancer, compounded by insufficient data on older protocols like everolimus with exemestane …

… and surgery. HR-positive breast cancers require estrogen to grow. … breast cancer. Research suggests that exemestane and anastrozole may reduce the risk of breast cancer … at treating ER-positive breast cancer. HR-positive breast cancers tend to grow …

… of early detection.³,⁵ Breast cancer treatment is highly … inhibitors (anastrozole, letrozole, exemestane) for postmenopausal women. … patients receiving trastuzumab. Breast cancer remains a critical … positioned to support breast cancer patients through our …

… Condition/Recommendation: Breast cancer, medication use to reduce … important. The protection against breast cancer is less likely to … of breast cancer—there was no difference in breast cancer deaths … results look worse; the exemestane study was lower than …

… (HR)-positive HER2-negative breast cancer that has certain genetic mutations … plus fulvestrant and everolimus plus exemestane – indirect comparisons suggest that … none available. “People with advanced breast cancer would value treatments like capivasertib …

… 47;HER2–) recurrent or metastatic breast cancer, optimal treatment after progression on … activity in HR+ breast cancer-derived cell lines and breast cancer xenograft models. … s choice of anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen not …